{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:54:31Z","timestamp":1775134471336,"version":"3.50.1"},"reference-count":27,"publisher":"Pharmaceutical Society of Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1248\/bpb.b18-00458","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T22:37:11Z","timestamp":1548974231000},"page":"173-178","source":"Crossref","is-referenced-by-count":7,"title":["Prophylactic Treatment with Intravenous Immunoglobulin Attenuates Experimental Optic Neuritis in Mice"],"prefix":"10.1248","volume":"42","author":[{"given":"Hiroyuki","family":"Takahashi","sequence":"first","affiliation":[{"name":"Pharmacology Research Department, Teijin Institute for Bio-medical Research, Teijin Pharma Limited"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachio","family":"Okuda","sequence":"additional","affiliation":[{"name":"KM Biologics Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuho","family":"Tamura","sequence":"additional","affiliation":[{"name":"Pharmacology Research Department, Teijin Institute for Bio-medical Research, Teijin Pharma Limited"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Kamei","sequence":"additional","affiliation":[{"name":"KM Biologics Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Aizawa","sequence":"additional","affiliation":[{"name":"Pharmacology Research Department, Teijin Institute for Bio-medical Research, Teijin Pharma Limited"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunefumi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Pharmacology Research Department, Teijin Institute for Bio-medical Research, Teijin Pharma Limited"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Lycke J, Tollesson PO, Fris\u00e9n L. Asymptomatic visual loss in multiple sclerosis. <i>J. Neurol.<\/i>, <b>248<\/b>, 1079\u20131086 (2001).","DOI":"10.1007\/s004150170029"},{"key":"2","unstructured":"2) Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. <i>Brain Pathol.<\/i>, <b>24<\/b>, 83\u201397 (2014)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Arnold AC. Evolving management of optic neuritis and multiple sclerosis. <i>Am. J. Ophthalmol.<\/i>, <b>139<\/b>, 1101\u20131108 (2005).","DOI":"10.1016\/j.ajo.2005.01.031"},{"key":"4","unstructured":"4) Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, Corbett J, Eggenberger E, Goodwin JA, Katz B, Kaufman DI, Keltner JL, Kupersmith MJ, Miller NR, Moke PS, Nazarian S, Orengo-Nania S, Savino PJ, Shults WT, Smith CH, Trobe JD, Wall M, Xing D, Optic Neuritis Study Group. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. <i>Am. J. Ophthalmol.<\/i>, <b>137<\/b>, 77\u201383 (2004)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Bennett JL, Nickerson M, Costello F, Sergott RC, Calkwood JC, Galetta SL, Balcer LJ, Markowitz CE, Vartanian T, Morrow M, Moster ML, Taylor AW, Pace TW, Frohman T, Frohman EM. Re-evaluating the treatment of acute optic neuritis. <i>J. Neurol. Neurosurg. Psychiatry<\/i>, <b>86<\/b>, 799\u2013808 (2015).","DOI":"10.1136\/jnnp-2014-308185"},{"key":"6","unstructured":"6) Wiles CM, Brown P, Chapel H, Guerrini R, Hughes RA, Martin TD, McCrone P, Newsom-Davis J, Palace J, Rees JH, Rose MR, Scolding N, Webster AD. Intravenous immunoglobulin in neurological disease: a specialist review. <i>J. Neurol. Neurosurg. Psychiatry<\/i>, <b>72<\/b>, 440\u2013448 (2002)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Berger M, McCallus DE, Lin CS. Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies. <i>J. Peripher. Nerv. Syst.<\/i>, <b>18<\/b>, 275\u2013296 (2013).","DOI":"10.1111\/jns5.12048"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Jacob S, Rajabally YA. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. <i>Curr. Neuropharmacol.<\/i>, <b>7<\/b>, 337\u2013342 (2009).","DOI":"10.2174\/157015909790031166"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. <i>N. Engl. J. Med.<\/i>, <b>367<\/b>, 2015\u20132025 (2012).","DOI":"10.1056\/NEJMra1009433"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Tselis A, Perumal J, Caon C, Hreha S, Ching W, Din M, Van Stavern G, Khan O. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. <i>Eur. J. Neurol.<\/i>, <b>15<\/b>, 1163\u20131167 (2008).","DOI":"10.1111\/j.1468-1331.2008.02258.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Nobuyoshi S, Kanamori A, Matsumoto Y, Nakamura M. Rescue effects of intravenous immunoglobulin on optic nerve degeneration in a rat model of neuromyelitis optica. <i>Jpn. J. Ophthalmol.<\/i>, <b>60<\/b>, 419\u2013423 (2016).","DOI":"10.1007\/s10384-016-0454-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Okuda S, Kamei S, Harano S, Shinya N, Hayashida K, Sasaki T. Enhancement of regulatory T cell induction by intravenous S-Sulfonated immunoglobulin during the treatment of experimental autoimmune encephalomyelitis. <i>Yakugaku Zasshi<\/i>, <b>132<\/b>, 243\u2013249 (2012).","DOI":"10.1248\/yakushi.132.243"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Matsunaga Y, Kezuka T, An X, Fujita K, Matsuyama N, Matsuda R, Usui Y, Yamakawa N, Kuroda M, Goto H. Visual functional and histopathological correlation in experimental autoimmune optic neuritis. <i>Invest. Ophthalmol. Vis. Sci.<\/i>, <b>53<\/b>, 6964\u20136971 (2012).","DOI":"10.1167\/iovs.12-10559"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Matsuda R, Kezuka T, Nishiyama C, Usui Y, Matsunaga Y, Okunuki Y, Yamakawa N, Ogawa H, Okumura K, Goto H. Suppression of murine experimental autoimmune optic neuritis by mature dendritic cells transfected with calcitonin gene-related peptide gene. <i>Invest. Ophthalmol. Vis. Sci.<\/i>, <b>53<\/b>, 5475\u20135485 (2012).","DOI":"10.1167\/iovs.12-9935"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Arumugam TV, Woodruff TM, Lathia JD, Selvaraj PK, Mattson MP, Taylor SM. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. <i>Neuroscience<\/i>, <b>158<\/b>, 1074\u20131089 (2009).","DOI":"10.1016\/j.neuroscience.2008.07.015"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Counts SE, Lahiri DK. Overview of immunotherapy in Alzheimer\u2019s disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD. <i>Curr. Alzheimer Res.<\/i>, <b>11<\/b>, 623\u2013625 (2014).","DOI":"10.2174\/156720501107140815102453"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Jeong S, Lei B, Wang H, Dawson HN, James ML. Intravenous immunoglobulin G improves neurobehavioral and histological outcomes after traumatic brain injury in mice. <i>J. Neuroimmunol.<\/i>, <b>276<\/b>, 112\u2013118 (2014).","DOI":"10.1016\/j.jneuroim.2014.08.626"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Pierson E, Simmons SB, Castelli L, Goverman JM. Mechanisms regulating regional localization of inflammation during CNS autoimmunity. <i>Immunol. Rev.<\/i>, <b>248<\/b>, 205\u2013215 (2012).","DOI":"10.1111\/j.1600-065X.2012.01126.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Quinn TA, Dutt M, Shindler KS. Optic neuritis and retinal ganglion cell loss in a chronic murine model of multiple sclerosis. <i>Front Neurol.<\/i>, <b>2<\/b>, 50 (2011).","DOI":"10.3389\/fneur.2011.00050"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kezuka T, Usui Y, Goto H. Analysis of the pathogenesis of experimental autoimmune optic neuritis. <i>J. Biomed. Biotechnol.<\/i>, <b>2011<\/b>, 294046 (2011).","DOI":"10.1155\/2011\/294046"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Lok KZ, Manzanero S, Arumugam TV. Neuronal low-density lipoprotein receptor-related protein 1 (LRP1) enhances the anti-apoptotic effect of intravenous immunoglobulin (IVIg) in ischemic stroke. <i>Brain Res.<\/i>, <b>1644<\/b>, 192\u2013202 (2016).","DOI":"10.1016\/j.brainres.2016.05.023"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Viviani B, Bartesaghi S, Corsini E, Galli CL, Marinovich M. Cytokines role in neurodegenerative events. <i>Toxicol. Lett.<\/i>, <b>149<\/b>, 85\u201389 (2004).","DOI":"10.1016\/j.toxlet.2003.12.022"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Chakfe Y, Seguin R, Antel JP, Morissette C, Malo D, Henderson D, S\u00e9gu\u00e9la P. ADP and AMP induce interleukin-1beta release from microglial cells through activation of ATP-primed P2X7 receptor channels. <i>J. Neurosci.<\/i>, <b>22<\/b>, 3061\u20133069 (2002).","DOI":"10.1523\/JNEUROSCI.22-08-03061.2002"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Weishaupt A, Kuhlmann T, Sch\u00f6nrock LM, Toyka KV, Br\u00fcck W, Gold R. Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis. <i>Acta Neuropathol.<\/i>, <b>104<\/b>, 385\u2013390 (2002).","DOI":"10.1007\/s00401-002-0568-y"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Yamasaki R. Role of microglia in inflammatory demyelination lesion in the central nervous system. <i>Clin. Neurol.<\/i>, <b>54<\/b>, 981\u2013983 (2014).","DOI":"10.5692\/clinicalneurol.54.981"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Kaneyama T, Takizawa S, Tsugane S, Yanagisawa S, Takeichi N, Ehara T, Ichikawa M, Koh CS. Downregulation of water channel aquaporin-4 in rats with experimental autoimmune encephalomyeritis induced by myelin basic protein. <i>Cell. Immunol.<\/i>, <b>281<\/b>, 91\u201399 (2013).","DOI":"10.1016\/j.cellimm.2013.01.003"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Rothhammer V, Borucki DM, Tjon EC, Takenaka MC, Chao CC, Ardura-Fabregat A, de Lima KA, Guti\u00e9rrez-V\u00e1zquez C, Hewson P, Staszewski O, Blain M, Healy L, Neziraj T, Borio M, Wheeler M, Dragin LL, Laplaud DA, Antel J, Alvarez JI, Prinz M, Quintana FJ. Microglial control of astrocytes in response to microbial metabolites. <i>Nature<\/i>, <b>557<\/b>, 724\u2013728 (2018).","DOI":"10.1038\/s41586-018-0119-x"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/2\/42_b18-00458\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T23:51:00Z","timestamp":1606348260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/2\/42_b18-00458\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b18-00458","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,1]]}}}